PH12020551343A1 - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer - Google Patents

7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Info

Publication number
PH12020551343A1
PH12020551343A1 PH12020551343A PH12020551343A PH12020551343A1 PH 12020551343 A1 PH12020551343 A1 PH 12020551343A1 PH 12020551343 A PH12020551343 A PH 12020551343A PH 12020551343 A PH12020551343 A PH 12020551343A PH 12020551343 A1 PH12020551343 A1 PH 12020551343A1
Authority
PH
Philippines
Prior art keywords
prophylaxis
treatment
liver cancer
derivatives
compounds
Prior art date
Application number
PH12020551343A
Other languages
English (en)
Inventor
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Sabine Hoves
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH12020551343A1 publication Critical patent/PH12020551343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PH12020551343A 2018-02-28 2020-08-27 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer PH12020551343A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Publications (1)

Publication Number Publication Date
PH12020551343A1 true PH12020551343A1 (en) 2021-06-21

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551343A PH12020551343A1 (en) 2018-02-28 2020-08-27 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Country Status (19)

Country Link
EP (1) EP3758707A1 (fr)
JP (1) JP7089596B2 (fr)
KR (1) KR20200128414A (fr)
CN (1) CN111801100B (fr)
AR (1) AR114419A1 (fr)
AU (1) AU2019228654A1 (fr)
BR (1) BR112020016509A2 (fr)
CA (1) CA3091950A1 (fr)
CL (1) CL2020002139A1 (fr)
CO (1) CO2020010306A2 (fr)
IL (1) IL276817A (fr)
MA (1) MA52412A (fr)
MX (1) MX2020008746A (fr)
PE (1) PE20211456A1 (fr)
PH (1) PH12020551343A1 (fr)
RU (1) RU2020131012A (fr)
SG (1) SG11202008291XA (fr)
TW (1) TW202003518A (fr)
WO (1) WO2019166432A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
HUE069183T2 (hu) 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
JP2025522978A (ja) * 2022-07-14 2025-07-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの処置のためのホスホリルプリノン化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
BR112012009329A2 (pt) * 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
CA3034185A1 (fr) * 2016-09-13 2018-03-22 F. Hoffmann-La Roche Ag Traitement combine avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hepatite b

Also Published As

Publication number Publication date
IL276817A (en) 2020-10-29
PE20211456A1 (es) 2021-08-05
CN111801100A (zh) 2020-10-20
KR20200128414A (ko) 2020-11-12
CL2020002139A1 (es) 2021-01-04
WO2019166432A1 (fr) 2019-09-06
EP3758707A1 (fr) 2021-01-06
TW202003518A (zh) 2020-01-16
MA52412A (fr) 2021-06-02
BR112020016509A2 (pt) 2020-12-15
CN111801100B (zh) 2023-10-24
MX2020008746A (es) 2020-09-28
RU2020131012A (ru) 2022-03-28
CO2020010306A2 (es) 2020-08-31
JP2021514972A (ja) 2021-06-17
AR114419A1 (es) 2020-09-02
JP7089596B2 (ja) 2022-06-22
SG11202008291XA (en) 2020-09-29
AU2019228654A1 (en) 2020-09-03
CA3091950A1 (fr) 2019-09-06

Similar Documents

Publication Publication Date Title
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12019500432B1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
MX2020007265A (es) Derivados de rapamicina.
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY190795A (en) Bromodomain inhibitors
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
NZ735249A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
PH12016502281A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam